Neuroendocrine neoplasms represent a heterogeneous group of cancers arising from a variety of neuroendocrine cell types. In general, these tumors (NET) are asymptomatic and are discovered late once metastatic disease is present (40-80%). The liver is the most common organ involved when metastases occur (40-93%), followed by bone (12-20%) and lungs (8-10%). A number of different therapeutic options are available for patients with hepatic metastases including surgical resection, transplantation, transarterial chemoembolization, radiofrequency and microwave ablation, radioembolization (Y90), chemotherapy, somatostatin analogues and molecular targeted therapies. Surgical resection is still considered the treatment of choice and provides excellent disease control with an overall survival of 47-92%. Liver transplantation has been advocated in selected patients with bilateral unresectable symptomatic liver metastases. The aim of this study is to review the existing literature emphasizing on the role of transplantation to treat patients with liver metastases from NET.
|Number of pages||7|
|Journal||Best Practice and Research: Clinical Endocrinology and Metabolism|
|State||Published - Jan 1 2016|
Bibliographical notePublisher Copyright:
© 2016 Elsevier Ltd.
- UNOS database
- liver metastases
- liver transplantation
- neuroendocrine tumors
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism